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Abstract
The aim of the present study was to prepare and evaluate a paclitaxel nanocrystal-based
formulation stabilized by serum protein transferrin in a non-covalent manner. The pure paclitaxel
nanocrystals were first prepared using an antisolvent precipitation method augmented by
sonication. The serum protein transferrin was selected for use after evaluating the stabilizing effect
of several serum proteins including albumin and immunoglobulin G. The formulation contained
approximately 55~60% drug and was stable for at least 3 months at 4 °C. In vivo antitumor
efficacy studies using mice inoculated with KB cells demonstrate significantly higher tumor
inhibition rate of 45.1% for paclitaxel-transferrin formulation compared to 28.8% for paclitaxel
nanosuspension treatment alone. Interestingly, the Taxol® formulation showed higher antitumor
activity than the paclitaxel-transferrin formulation, achieving a 93.3% tumor inhibition rate 12
days post initial dosing. However, the paclitaxel-transferrin formulation showed a lower level of
toxicity, which is indicated by steady increase in body weight of mice over the treatment period.
In comparison, treatment with Taxol® resulted in toxicity issues as body weight decreased. These
results suggest the potential benefit of using a serum protein in a non-covalent manner in
conjunction with paclitaxel nanocrystals as a promising drug delivery model for anticancer
therapy.
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1. Introduction
Paclitaxel is a naturally occurring diterpenoid extracted from the bark of the Pacific yew tree
(Taxus brevifolia) [1]. In clinical trials paclitaxel has demonstrated antitumoral activity
through high-affinity binding to microtubules, stabilizing and enhancing tubulin
polymerization and suppression of spindle microtubule dynamics [2–4]. These activities
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effectively inhibit cell mitosis, motility and intracellular transport, which lead to apoptotic
cell death. Unfortunately, clinical advances of paclitaxel in its natural form have been
limited by its physicochemical property, more specifically its poor aqueous solubility (~0.3
µg/ml) [5]. The lack of a functional group in the structure of the paclitaxel molecule makes
chemical modification of the natural molecule to increase solubility difficult [6]. Therefore,
the selection of appropriate delivery platforms to delivery paclitaxel is particularly crucial to
the clinical advancement of this antitumor compound.
Various paclitaxel delivery systems have been investigated to improve the solubility and
pharmacological properties of paclitaxel, including micelles, liposomes, microparticles,
nanoparticles and the use of cosolvents and cyclodextrins [7–10]. The most widely known
delivery platform is a cosolvent system consisting of a 50:50 mixture of Cremophor EL® (a
polyoxyethylated castor oil) and ethanol. The corresponding formulation (Taxol® or generic
equivalents) consists of paclitaxel dissolved at a concentration of 6 mg/ml in the
aforementioned cosolvent system, and is administered intravenously following dilution with
normal saline or 5% dextrose solution[11]. While this approach overcomes the limiting
solubility of paclitaxel, the use of Cremophor EL has been associated with serious and dose-
limiting toxicities. More specifically, Cremophor EL has been known to leach plasticizers
from standard intravenous tubing, releasing di(2-ethylhexyl)phthalate (DEHP)[1]. The
infusion of DEHP has been demonstrated to produce a histamine release and result in
hypersensitivity reactions in 20~40% of unpremedicated patients in phase I clinical
trials[12]. Furthermore, Cremophor EL has also been associated with hyperlipidemia,
erythrocyte aggregation, sensory neuropathy and neutropenia [13–15]. Clearly there is a
need to develop alternative delivery systems for paclitaxel that enhance drug solubility while
eliminating adverse reactions.
A possible alternative delivery system for paclitaxel is a nanosuspension formulation. A
nanosuspension consists of nanosized, crystalline particles that may or may not be stabilized
by a suitable stabilizer or multiple stabilizers [16, 17]. Nanosuspension formulations of
several drugs are already marketed, including Rapamune® (sirolimus), Emend® (aprepitant)
and Tricor® (fenofibrate)[18]. There are several advantages to using nanosuspension
formulations for delivery of anticancer agents such as paclitaxel: (i) nanosized particles can
enhance dissolution velocity and saturation solubility of a poorly soluble drug as predicted
by the Noyes-Whitney and Ostwald-Freundlich principles, which usually leads to increasing
bioavailability [19]; (ii) nanocrystalline particles require no solubilizing chemicals, therefore
it’s possible to achieve high drug loading [20] and (iii) nanosized particles may lead to better
antitumor efficacy via the enhanced permeation and retention effect, which is associated
with extravasation and retention of particles in the vicinity of the tumor [21]. Given these
advantages, there has been increasing interest in formulating anticancer drugs into
nanosuspension formulations.
Techniques to produce nanosized crystalline particles can be categorized into top-down
technologies such as milling and high pressure homogenization, and bottom-up methods
such as precipitation and self-assembly[22–26]. Commonly used top-down methods have
limitations such as the need for repeated milling cycles, as well as the potential for
contamination from erosion of milling materials. High pressure homogenization in particular
requires a relatively high number of cycles to achieve sufficient particle size reduction,
which increases cost and risk of contamination and product degradation. The precipitation
method involves dissolving the drug in a solvent and then adding it to a non-solvent, which
leads to the production of finely dispersed, precipitated drug. Compared to top-down
techniques, a major advantage of the precipitation method is its relative simplicity and low
cost. However, since solvents are used in this process, solvent choice and removal are
important issues to take into consideration. Furthermore, the size of the nanocrystals can be
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hard to control. The stability of the nanocrystals is a major concern; particle aggregation and
growth can occur and should be prevented[27].
To stabilize nanocrystal formulations, typical strategy includes the addition of hydrophilic
polymers and/or surfactants to the nanosuspensions. Stabilization is achieved through
repulsion by either steric or electrostatic hindrance, whereby these polymers or surfactants
adsorbed onto the surface of the nanocrystals and/or alter the dielectric constant of the liquid
environment. Commonly used stabilizers include semi-synthetic non-ionic polymer such as
hydroxypropyl methylcellulose (HPMC), synthetic linear polymers such as
polyvinylpyrrolidone (PVP) and polyethylene glycol (PEG 400), synthetic copolymers such
as Pluronic® F127 and F68, ionic surfactants such as sodium dodecyl sulfate (SDS) and non-
ionic surfactants such as polysorbate esters Tween® 20 and Tween® 80 [28].
Another possible strategy is the use of proteins as stabilizers. In particular, proteins found
naturally in the body, such as serum proteins, present an attractive alternative to the
traditional stabilizers. Proteins have been widely used in the past as emulsifiers that help to
stabilize oil-in-water emulsions [29]. Theoretically, serum proteins, such as albumin, may
also provide a stabilizing effect to nanocrystals because they have been known to adsorb
onto hydrophobic surfaces with a certain degree of binding affinity and therefore may
provide steric hindrance to nanocrystal aggregation and growth [30, 31]. In preliminary
studies, it was found that the presence of serum in a drug nanosuspension resulted in
effective inhibition of particle size increase during subsequent centrifugation and drying
procedures compared to the absence of serum in nanosuspension (data not shown). The
presence of serum was also found to inhibit aggregation of nanocrystals in an aqueous buffer
environment. Therefore, it seems that serum proteins may be likely candidates for stabilizing
nanosuspensions. In addition to stabilizing effects, a potential advantage of using serum
proteins over traditional polymer or surfactant-based stabilizers is the ability to bind certain
membrane proteins that are often present in tumorous cells [32]. The ability to bind receptor
proteins present in tumor cell membranesis a property that is particularly valuable in
antitumor treatments since it may facilitate targeting of anticancer drugs to the tumor site
[33].
The present study describes the development and evaluation of paclitaxel nanosuspension
formulations with serum protein as a stabilizer. Serum protein was successfully fractionated
into different fractions and analyzed for maximal stabilizing effect. The major components
of the most effective fraction (as determined by SDS-PAGE) were then analyzed further as
potential stabilizers for the paclitaxel nanosuspension formulation. To the authors’
knowledge, the formulation described herein is a novel approach to the development of
nanoparticle-based antitumor treatment in the sense that serum protein was used as a
stabilizer in a non-covalent manner. Human KB nasopharyngeal epidermal carcinoma cells
and SKOV-3 ovarian cancer cell models were used to assess the in vitro antitumor efficacy
of the formulation. The data obtained from KB cells were compared to data from mice
models to assess the in vivo performance of the paclitaxel nanosuspension formulation.
2. Materials and methods
2.1.Preparation of paclitaxel nanocrystals
Paclitaxel (PTX) was supplied by Samyang Genex Corporation (Daejeon, Korea)
Nanocrystals were prepared by an antisolvent precipitation process supplemented by
sonication. In brief, 1 ml solution of PTX was injected into deionized water with or without
polymers or surfactants at 4°C under rapid stirring (1200 rpm) and intense sonication
(FS20D Bath Sonicator, Fisher Scientific, Waltham, MA). The solvents evaluated were
methanol, ethanol, methylene chloride (DCM), ethyl acetate (EA) and dimethyl sulfoxide
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(DMSO) (Sigma Aldrich, St. Louis, MO). The polymers and surfactants were chosen from
HPMC (Hercules Inc., Wilmington, DE), PVP (Dow Chemical Company, Midland, MI),
PEG 400 (Sigma Aldrich, St. Louis, MO), Pluronic F127 and F68 (BASF, Florham Park,
NJ),SDS (Sigma Aldrich, St. Louis, MO), Tween 20 and Tween 80 (Sigma Aldrich, St.
Louis, MO). Processing conditions (solvent-to-antisolvent ratio, stirring speed, mixing time)
were evaluated for their ability to produce stable nanosized particles less than 300 nm within
20 minutes of processing. A detailed flow chart of how the final process parameters were
optimized is presented in Figure 1.
2.2. Preparation of formulation
Serum protein fractionation—Human serum (type AB, male, Sigma Aldrich, St Louis,
MO) was separated into several fractions according to a modified cold ethanol plasma-
protein precipitation process[34, 35]. In brief, three stock solutions were prepared: 4 M
sodium acetate buffer, 10 M acetic acid and 53.3% (v/v) ethanol-water mixture were
prepared by standard practices. Each fraction of serum proteins was obtained by carefully
controlling the ionic strength, pH and polarity of the processing buffer environment. The
ionic strength, pH and polarity of buffers were controlled by varying composition of the
three stock solutions from above. Each fraction was separated from the rest by
centrifugation at 3500× g for 10 minutes. Serum proteins were separated using the procedure
described in Figure 1 into a total of 4 fractions and freeze dried. The fractions were stored at
−20 °C until further use.
SDS-Polyacrylamide gel electrophoresis—The serum protein fractions were
characterized for their composition using SDS-PAGE by standard established procedures.
Polyacrylamide gels composed of 10% stacking and 5% resolving gel were prepared. After
electrophoresis, the gels were stained by Coomassie Blue and then de-stained with methanol
and glacial acetic acid. The molecular weight of the protein bands was determined by
electrophoresis of a standard molecular weight marker protein (Bio-Rad, Hercules, CA).
Formulation development—PTX nanocrystals were prepared according to procedures
outlined previously in this manuscript. A certain amount of PTX nanocrystals was
suspended in deionized water and added to a solution of serum protein fractions 1–4, serum
protein human serum albumin (HSA), transferrin (Trf) or immunoglobulin G (IgG) (Sigma-
Aldrich, St Louis, MO) in a drop-wise fashion under gentle stirring. When the addition of
PTX nanosuspension was complete, the mixture continued to be gently stirred for another 15
minutes before centrifugation at 4 °C andfreeze drying. The formulation composition (PTX
to serum fraction or serum protein ratio) was evaluated for its ability to produce stable
nanosuspensions with minimal particle size change after freeze drying. In addition, the final
target formulation should have a composition of at least 25% drug loading.
2.3. Characterization of formulation
Particle size and zeta potential analysis—The mean particle size and the
polydispersity index (PDI) were measured by dynamic light scattering (90Plus Particle Size
Analyzer, Brookhaven Instruments, Holtsville, NY). Zeta potential (ZP) was measured by
the same instrument equipped with a zeta potential analyzer. For sample preparation,
approximately 1 mg of freeze dried sample was suspended in 4 ml of redistilled water and
vortexed for 5 minutes followed by sonication for 30 seconds to disperse the sample
throughout the medium. A suitable scattering intensity was selected for collecting final
measurements. The particle size, PDI and ZP were measured in triplicate.
Particle morphology—Particle morphology was characterized by scanning electron
microscope (SEM) (FEI Nova™ NanoSEM, FEI, Hillsboro, OR) and atomic force
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microscope (AFM) (Bioscope Catalyst®, Bruker Instruments, MA). Samples for
characterization by SEM were prepared by carefully depositing a small amount of freeze-
dried sample onto the surface of aluminum stubs and sputter coating with a conductive layer
of platinum for 1 minute under vacuum conditions.
Physical state characterization—The solid form of pure PTX and formulation were
characterized by powder X-ray diffraction (PXRD) (Siemens Bruker D5000, Bruker AXS,
Madison, WI) using CuK radiation at 30 mA and 45 kV (scanning rate 0.4°/min), and
diffraction angles (2θ) of 3–40°. Samples for PXRD were prepared by crushing a desired
amount of pure or freeze-dried nanosuspension with mortar and pestle before adding to the
sample holder. Excess powder sample was scraped away and the surface of the powder
sample was leveled with a glass slide.
Storage stability study—PTX formulation was stored at 4°C over a period of 3 months.
Particle size, PDI and ZP of the storage samples were measured at 0, 1, 2 and 3 months. In
addition, solid form characterization using PXRD was carried out for samples stored for 3
months at 4°C for physical stability assessments.
Drug content—The amount of PTX in the formulation was determined by accurately
measuring out 5 mg of freeze-dried nanosuspension formulation and re-suspending in 1 ml
of deionized water by vortexing and sonication. Approximately 10 ml of coldethanol was
then added to the suspension and vigorously mixed by vortexing and sonication for 20
minutes. Following centrifugation of this solution for 5 minutes at 5,000 rpm, the
supernatant containing dissolved PTX was collected. The pellet containing precipitated
protein was washed with cold ethanol. The centrifugation and washing procedures were
repeated at least 3 times, each time the supernatant was collected and combined. The PTX
solution was rotary evaporated then re-dissolved in 10 ml of mobile phase for analysis by
HPLC. The HPLC system (Agilent 1100 series, Agilent, Santa Clara, CA) was equipped
with an autosampler, in-line degasser and an UV absorbance detector. Separation was
achieved using a Phenomenex C-18 (250 mm × 4.6 mm) analytical column (Torrance, CA)
at a flow rate of 1 ml/min, a detection wavelength of 228 nm and an injection volume of 20
µl. The mobile phase consisted of water, acetonitrile and methanol (40:30:30 v/v). Samples
and mobile phase were filtered through a 0.22 µm syringe filter and a 0.48 µm membrane
filter respectively prior to use. Drug content was calculated using the following equation:
In vitro dissolution—PTX release was carried out by suspending an accurately measured
amount of freeze-dried PTX formulation in phosphate buffered saline (PBS, pH 7.4) and
transferring the suspension into dialysis membrane cassettes (Slide-A-Lyzer G2, Thermo
Scientific, Rockford, IL) with a molecular weight cut-off of 3500 Da. The cassettes
containing PTX nanosuspensions were submerged in PBS buffer solution at 37±1 °C in an
incubator under constant shaking(100 rpm). Sink conditions were maintained: the maximum
theoretical concentration of the dissolved drug was < 1 % of the saturation concentration. At
predetermined intervals, samples were withdrawn from outside the membrane cassettes to be
analyzed by HPLC. The volume removed was replaced by fresh buffer. The samples were
filtered through a 0.2 µm cellulose acetate filter with low protein binding before the analysis
of the drug concentration. The samples were analyzed by HPLC according to the procedure
outlined above. Experiments were performed in triplicate.
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2.4.In vitro cytotoxicity of formulation
Cell culture—Human KB epidermal carcinoma cells and SKOV-3 ovarian cancer cells
were obtained from Dr. Yoon Yeo’s lab (Purdue University). Cell culture media FA-
deficient RPMI-1640 supplemented with 10% fetal bovine serum, 100 U/mL penicillin and
100 µg/mL streptomycin and Dulbecco’s Modified Eagle Medium (DMEM) supplemented
with 10% (v/v) heat-inactivated fetal bovine serum (FBS) were obtained from Life
Technologies Co., Grand Island, NY. Human KB epidermal carcinoma cells were cultured
at 37 °C with FA-deficient RPMI-1640in a humidified atmosphere of 5% CO2 and 90%
relative humidity (Nuaire Incubator, Plymouth, MN). The cells were passaged upon
reaching approximately 90% confluence from T-flasks using 0.25% trypsin-EDTA (Sigma
Aldrich, St. Louis, MO). SKOV-3 ovarian cancer cells were cultured in DMEM at 37 °C
under a humidified atmosphere containing 5% CO2. The cells were also passaged upon
reaching approximately 90% confluence from T-flasks using 0.25% trypsin-EDTA.
Cytotoxicity study—This method was comparable to those previously reported for in
vitro cytotoxicity studies. KB cells were seeded in a 96-well plate at a density of 5 × 104
cells /well. SKOV-3 cells were seeded in a 96-well plate at a density of 4×105 cells / well.
PTX formulation was suspended in buffer at 10 mg/ml and further diluted from 10 mg/ml to
1 × 10−8 mg/ml for measurement. Transferrin solution was also diluted in buffer at the same
concentration values. The cells were then exposed to a suspension or solution at 37 °C for 72
hours. After washing once with PBS to remove the samples, a total volume of 20 µl of 5 mg/
ml MTT solution was added to each well and the plates were further incubated for 240
minutes at 37 °C in the dark. The culture medium was subsequently discarded, and 150 µl of
DMSO was added to dissolve the dark-blue formazan crystals. Cell proliferation and
viability were quantified spectrophotometrically by measuring the absorbance of the
formazan product at a wavelength of 490 nm using a microplate reader (Bio-Rad Model 550,
Bio-Rad, Hercules, CA). Cell viability was calculated using the following equation:
Where Ints is the absorbance intensity of the cells incubated with the PTX formulations and
Intcontrol is the absorbance intensity of the cells incubated with the culture medium only.
2.5. In vivo antitumor measurement
Formulation—As a positive control, 30 mg of PTX was dissolved in a 50:50 mixture of
Kolliphor® EL (Sigma Aldrich, St. Louis, MO) and ethanol at room temperature. Prior to
administration in animals, the stock solution was diluted 1:15 with 0.9% saline solution
(sterilized by filtration through 0.2 µm filter) to a final concentration of 2 mg/ml. PTX
nanocrystals were also suspended to the same concentration in 0.9% saline for
administration.
Animal model—Female nude outbred mice (Tac:Cr: (NCr)-Foxn1 Nu) were obtained
from Taconic (Hudson, NY) at 4–5 weeks of age (15–20g)and kept under SPF conditions for
1 week before the study. All of the animal experiments comply with the principles of care
and use of laboratory animals and were approved by the Institutional Animal Care and Use
Committee of Purdue University. The tumor model was established by subcutaneous
injection of 5 × 106 KB cells into the right armpit region of each nude mouse. When tumors
had developed to approximately 300 mm3 (one week after initial inoculation), the KB-
bearing mice were randomly divided into 4 groups (n = 6). Saline was used as negative
control; the dose was 20 mg/kg for PTX solution or PTX nanosuspension formulation. At
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Day 7, 11 and 15 after the cell inoculation, the respective treatments were given
intravenously to each animal via the tail vein. Tumor size was monitored every other day
with a caliper in two dimensions (length and width). The tumor volume was estimated using
the following equation:
The body weight of each mouse was also monitored every other day as an index of systemic
toxicity. The mice were euthanized on Day 19 and the tumors were excised and weighed.
The tumor inhibition rate was calculated by the following equation:
where Wcontrol and Wtreated are the tumor weights of mice treated by saline and PTX
solution or nanosuspension respectively.
2.6. Statistical analysis
Results from in vitro cytotoxicity and in vivo antitumoral activity experiments were
evaluated by the unpaired t-test (between two groups) or one-way ANOVA (between
multiple groups) with Tukey’s multiple comparison tests. When p-values were less than
0.05, statistical significance was considered achieved.
3. Results and Discussion
3.1. PreparingPTX nanocrystal
The optimization process to obtain stable PTX nanocrystals is described in Figure 1. The
optimization of PTX nanocrystals to meet our minimum requirements of less than 300 nm in
average particle size and within 20 minutes of processing time is dependent on several
parameters. First of all, the selection of solvent is an important factor. Methanol, ethanol,
DCM, EA and DMSO were selected for initial assessment based on having at least some
degree of miscibility with water, since water was the antisolvent of choice for our
applications. Another consideration in selecting these solvents is that PTX has a relatively
high solubility in them, which facilitates the formation of smaller particles [36]. Preliminary
size characterization results show that DCM, EA and DMSO produced significantly
(p<0.05) larger PTX nanocrystals compared to methanol and ethanol, with no significant
(p=0.7524) difference in particle size between methanol and ethanol. The specific values for
average particle size and PDI are summarized in Table 1. The tendency for DCM, EA and
DMSO to produce larger nanocrystals can be rationalized based on the slow diffusion rate of
DCM, EA and DMSO in water (as indicated by the smaller diffusion coefficient values)
compared to methanol and ethanol, which favors the formation of a smaller number of
crystal nuclei and larger particles during the precipitation process [37]. Ethanol was selected
as the solvent of choice for our applications over methanol due to its lower toxicity as
classified by ICH Guidelines. While use of methanol should be limited because of its
inherent toxicity (limited to 600 ppm or less), ethanol poses a lower risk to human health
and can be tolerated up to 5000 ppm per day. The morphology of PTX nanocrystals
prepared showed rod-like morphology regardless of type of solvent used.
The concentration of PTX in the solvent phase is another important factor. In the
optimization process it was found that 3 mg/ml PTX in ethanol is the optimum concentration
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required to meet the minimum requirements. The use of drug concentrations above this level
increases particle size (Table 1). When the drug concentration is increased from 3 mg/ml the
nanocrystal size increased dramatically. This increase in particle size as the drug
concentration in solvent increases has been observed in other studies [38] and is attributed to
a higher level of supersaturation that increases particle growth and reduces diffusion rate of
crystal nuclei between solvent and antisolvent, both conditions that lead to a larger final
particle size [39, 40]. At a lower concentration of 1 mg/ml PTX in solvent, particle size was
not significantly different from that of PTX at 3 mg/ml (p = 0.6553), which has also been
observed in antisolvent precipitation studies involving other drugs [41].
The volume ratio of water to ethanol is also critical to this process. An antisolvent-to-solvent
ratio of 20:1 was necessary to achieve stable nanocrystals that met the requirements (Table
1). Below this ratio the particle size increased significantly (p<0.05). This has also been
observed in numerous other studies [41–43]. A generally accepted explanation is that at a
given drug content in the system, the degree of supersaturation is increased when the ratio of
antisolvent to solvent is increased. A higher degree of supersaturation leads to a greater
nucleation rate, which promotes smaller particle size. At low antisolvent to solvent ratios,
the nucleation rate is high but the effect is counteracted by the increase in growth rate due to
higher solvent phase ratio, and the kinetics favor overall particle growth. Above antisolvent-
to-solvent ratio of 20:1, no further decrease in nanocrystal size was seen. This is most likely
due to the equilibrium between nucleation and growth processes [44].
A final consideration is the use of hydrophilic polymers or surfactants that may improve
physical stability of nanocrystals [45]. Interestingly, in most cases the presence of polymers
and surfactants in the antisolvent phase resulted in an increase in nanocrystal size compared
to pure water alone as the antisolvent (Table 1).A possible explanation is that the presence
of polymers and surfactants in the antisolvent increased the solubility of the drug in water.
The solubility enhancing effect of surfactants and polymers has been commonly observed in
the formulation of poorly water-soluble drugs [46, 47]. The enhancement of drug solubility
in the antisolvent phase reduces the solubility difference between the drug in the solvent and
the antisolvent phases, which may be associated with a decrease in the rate of precipitation.
In addition, increased solubilization could play a role in enhancing particle growth by
Ostwald ripening, since this process is heavily dissolution-dependent. An alternative
explanation is that the stabilizers decrease electrostatic repulsion between drug crystals by
either adsorbing to the surface of nanocrystals and / or altering the dielectric constant of the
liquid medium [48]. In this study, HPMC, PVP and Pluronic® F68 resulted in significant
reductions (less negative) ZP compared to the control; however PEG400, Tween® 20 and
SDS all had greater ZP values (more negative) but still resulted in bigger nanocrystals.
Clearly electrostatic repulsion cannot fully explain why the use of polymers and surfactants
increased particle size. Regardless, no stabilizer was used during the preparation of the PTX
nanocrystals.
In summary, we found that 3 mg/ml PTX solution in ethanol introduced into an aqueous
antisolvent phase at a ratio of 1:20 was critical to achieving stable PTX nanocrystals after 10
minutes of processing at a stirring speed of 1200 rpm augmented with sonication.
3.2. Development of stable formulation
The optimized process described above resulted in the production of PTX nanocrystals
suspended in an aqueous medium. For practical applications, it is more beneficial to have
the PTX nanocrystals in dried form. Upon further processing to collect and dry the PTX
nanocrystals, it was found that the average particle size of PTX nanocrystals increased by
115±10% after centrifugation and drying. This was expected, as during the centrifugation
process particles are brought into close proximity that facilitate collision and particle
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‘sticking’, a process that ultimately resulted in particle aggregation and size increase.
Clearly, excipients need to be added to prevent particle aggregation from occurring. In
preliminary assessments, human serum was found to effectively inhibit PTX nanocrystal
size increase during subsequent centrifugation and drying procedures compared to the
control. In addition, the presence of serum also inhibited PTX nanocrystal aggregation for at
least 7 days in a buffer environment. It is possible that serum proteins formed a stabilizing
layer on the surface of the nanocrystals that prevented particle collision and formed larger
particles. However, due to the complexity of human serum proteasome [32], it would be
more significant for practical applications if one or two specific serum protein or proteins
can be identified for their ability to stabilize the PTX nanocrystals. While it is beyond the
scope of this work to isolate every single serum protein and individually investigate their
ability to stabilize PTX nanocrystals, a more manageable approach was taken, whereby
serum proteins were fractionated into several large categories, and each category was
investigated for their contribution towards PTX nanocrystal stabilization. Fractions with
high levels of effect are then studied further.
Using the modified cold ethanol protein precipitation method outlined in the ‘Methods’
section, the serum was successfully separated into 4 fractions, designated Fractions I–IV
herein this manuscript. The SDS-PAGE analysis of the 4 fractions is demonstrated in Figure
2. Based on these data, several observations can be made. First, fractions I – IV all contained
varying amounts of human serum albumin (HSA), the most abundant plasma protein in the
blood. The presence of HSA in all fractions was expected due to the abundance of this
protein in the serum [1]. The band above HSA around 80 kDa is most likely Trf, which is
present in fractions I and IV but not fractions II and III. With the exception of fraction IV,
all other fractions also display a very faint band at 25 kDa that is most likely the γ globulin
light chain. Fraction I and III also show broad bands at a high molecular weight of around
150 kDa that suggest the presence of immunoglobulin G (IgG). It is noted that there are
overlaps in major components of fractions identified from this experiment. This is most
likely due to the limited ability to control pH and ionic strength, since in this particular
fractionation method, minute deviations in these parameters may lead to huge differences in
the types of proteins being precipitated. However, this was not deemed unacceptable for this
particular study since the end goal was to simply separate the serum into several different
fractions in some way such that each fraction can be monitored for interaction with PTX
nanocrystals individually.
The fractions from above displayed a different degree of size change inhibition in PTX
nanocrystals (Figure 3). Fraction IV was the most effective at inhibiting particle size
increase during subsequent centrifugation and drying, with a size increase of 34.5±5.9%
compared to 69.0±10.9% for fraction I, 71.4±12.5% for fraction II and 69.4±8.9% for
fraction III. Based on the SDS-PAGE analysis, it can be seen that the major protein
components of fraction IV are HSA and Trf, as indicated by strong bands around ~64 kDa
and ~80 kDa. Interestingly, fraction I also displays strong bands around these molecular
weights, indicating the presence of HSA and Trf as well. However, in presence of similar
concentrations of fraction I and IV, PTX nanocrystal size change was significantly higher
(p<0.05) in I than in IV.It is possible that the presence of Ig (which is present in greater
amounts in fraction I but not in IV) and in particular IgG had the opposite effect on PTX
nanocrystal stabilization, leading to aggregation that counteracted the stabilizing effect of
HSA and Trf.
To study this result further, the effect of HSA, Trf and IgG were examined individually. The
results are presented in Table 2. In general, for both HSA and Trf, the ability to stabilize
PTX nanocrystals shows a concentration dependent effect. Increasing protein concentration
decreased the extent of PTX nanocrystal size change. The presence of higher concentrations
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of HSA or Trf may have resulted in increased viscosity of the fluid, which may act to hinder
PTX nanocrystal diffusion and reduce the nanocrystals’ ability to collide into one another to
form larger particles. Furthermore, it is highly possible that the adsorption of HSA or Trf
molecules on the surface of PTX nanocrystals acted as a barrier to prevent nanocrystals from
aggregation. The data displayed in Table 2 shows that Trf was the most effective stabilizer
of PTX nanocrystals when similar concentrations of Trf and HSA were used. By the
addition of 4 mg/ml Trf solution to PTX nanocrystals the average size increased by only
5.57±2.7% after centrifugation and drying. The increase in particle diameter of
approximately 16 nm (or 8 nm in radius) corresponds well with the dimension of a single
layer of Trf molecules [49]. The results imply that the adsorption of Trf to PTX nanocrystals
most likely resulted in better stabilization of particles during subsequent processing due to
the larger size of the Trf protein compared to HSA (~4 nm in monolayer thickness [30])
which can be rationalized based on the increased distance between particles and steric
effects. Furthermore, Trf content in the formulation is also significantly higher than HSA,
which could be attributed to a higher amount of Trf being pelleted during the centrifugation
process due to its higher molecular weight. This may also have increased PTX nanocrystal
stability in the nanosuspension.
On the other hand, the data seem to suggest that IgG induces particle aggregation. When IgG
solution was added to PTX nanocrystals, the measured particle size of the formulation
increased more than the samples processed without IgG present. However, the dramatic
increase in measured particle size is most likely influenced by the aggregation of IgG
proteins rather than PTX nanocrystals, as seen in the control where pure IgG solution
without PTX nanocrystals was processed and subsequent particle size measurement also
showed a significant size increase. The tendency for immunoglobulins to aggregate as a
result of agitation has been demonstrated elsewhere [50]. To prevent IgG aggregation,
suggested strategies include lowering pH and addition of organic osmolytes such as sucrose
at a concentration of 10 %. When an IgG solution with a pH at 4.5 was used in the
formulation, increase in particle size was reduced significantly. The particles were very
well-stabilized when 10 % sucrose was added to the IgG solution, with almost no change in
particle size after processing. The results above suggest that IgG can be an effective
stabilizer for PTX nanocrystals if immunoglobulin aggregation can be prevented.
Based on the results and discussion above, Trf was selected as the stabilizer serum protein of
choice for PTX nanocrystals.
3.3. Characterization of formulation
X-ray diffractograms of PTX-Trf in comparison with the drug alone, PTX nanocrystals and
the physical mixture of the drug and Trf are shown in Figure 4. Average particle size for the
PTX-Trf formulation was 303.5 nm with PDI of 0.239.The addition of Trf increased average
particle size slightly with no significant influence on PDI of resultant particles. The increase
in particle diameter of approximately 16 nm (or 8 nm in radius) corresponds well with the
dimension of a single layer of Trf molecules [49]. Drug content of the PTX-Trf formulation
was approximately 55–60%as determined by HPLC analysis. The crystallinity of PTX is
confirmed with retention of characteristic peaks in X-ray diffractograms.Dominant peaks at
2θ angles between 4° and 7° and between 10° and 15° were still observed in PTX
formulations (nanocrystals with and without Trf).The X-ray diffraction patterns were
superimposable for the formulation tested before and after 3 months’ storage at 4 °C, which
implies that no physical form changes had taken place during the storage period.
The stability of the formulation was also confirmed with particle size, PDI and ZP
measurements taken at 1 month intervals throughout the storage period. Particle size, PDI
and ZP of the PTX-Trf formulationduring 3 months’ storage at 4 °C are shown in Table 3.
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The formulation was also imaged by SEM and AFM to confirm particle size reported by
dynamic light scatterin g (DLS), since DLS approximates particle size by measuring the
diffusion coefficient and is therefore more accurate when used to measure particle sizes of
spherical particles. Manual measurements taken from SEM and AFM images showed an
average particle size of 277.8 ± 23.9 nm, which is closely reflected in DLS measurements.
Particle size, PDI and ZP showed no significant changes over the period of 3 months. The
maintenance of average particle size and PDI precludes the possibility that Ostwald ripening
took place.
The dissolution profiles of PTX and its respective formulations (nanocrystal with or without
Trf) were evaluated in PBS at pH 7.4. As shown in Figure 5, both PTX nanocrystals and
PTX-Trf formulations showed significantly higher dissolution rates in comparison to the
control. More than 20% and 35% of PTX nanocrystals and PTX-Trf were released within 50
hours, respectively, whereas less than 5% release was achieved after 50 hours for PTX as
received from the manufacturer. The increased rate of dissolution is likely due to the small
size and large surface area of PTX nanocrystals as predicted by the Noyes-Whitney
equation. According to this equation, dissolution velocity dC / dt is proportional to the
concentration gradient A(Cs – Cx)/h, where A is the surface area of the solid, Cs is the
concentration of the solid in the diffusion layer, Cx is the bulk concentration of the solid and
h is the diffusion layer thickness [51]. The nanonization of the drug particles leads to large
increase in particle surface area, which leads to increased dissolution velocity. An additional
effect of nanonization is reduced diffusion layer thickness, which also contributes to an
increase in the dissolution rate. This is in agreement with our experimental dissolution
results. Rather interestingly, the Trf formulation showed a lower dissolution rate compared
to pure PTX nanocrystals. A possible explanation is the binding of Trf to molecular forms of
PTX which prevented passage of PTX molecules from within the membrane cassette to the
surrounding medium. This may potentially be beneficial for the delivery of PTX
nanocrystals in chemotherapy because it may prolong circulation and premature loss of
PTX.
3.4. In vitro cytotoxicity of PTX formulations
Cytotoxicity of PTX formulations was evaluated in cancerous KB and SKOV-3 cell lines.
The half maximal inhibitory concentrations (IC50) were determined from the concentration-
dependent cell viability curves as shown in Figure 6. For pure PTX nanosuspensions, the
IC50 were on the scale of 1.0 E-5 mg/ml in KB cells and 1.0 E-4 mg/ml in SKOV-3 cells
respectively. For PTX-Trf nanosuspension, the IC50 values were on the same order of
magnitude. There was no statistically significant difference between the IC50 values of PTX
nanosuspension and PTX-Trf nanosuspension in both cell lines. The concentration-
dependent cell viability curves for PTX and PTX-Trf were virtually superimposable. The
similar cytotoxicity profile can be explained based on the fact that both PTX nanocrystals
and PTX-Trf were incubated with the cells for 72 hours before being subjected to a MTT
assay and analyzed for results. As such both PTX nanocrystals and PTX-Trf were likely to
be dissolved in the medium due to the small size of particles, leading to similar cytotoxic
performance overall. In comparison, the IC50 data seems to suggest that PTX and PTX-Trf
nanosuspension formulations were more potent against KB cells than SKOV-3 cells. It is
possible that the difference in response is due to differences in cell line properties. To the
best of our knowledge, no other studies have compared potency of PTX and PTX-based
formations across these cell lines. Further study may be needed to clarify this difference,
which is outside the scope of the current study.
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3.5. In vivo antitumor effect of PTX formulations
At a dose of 20 mg/kg, PTX solution, PTX nanosuspension and PTX-Trf nanosuspension
were administered to each KB bearing mouse via tail vein on Day 7, 11 and 15 after initial
tumor cell inoculation. As a negative control, saline solution was also given via the tail vein
to mice in the control group in the same manner. The tumor progression results are shown in
Figure 7. The data indicates that both PTX nanosuspension and PTX-Trf nanosuspension
yielded significant tumor inhibition in comparison to the negative control group. In
particular, the treatment from PTX-Trf was significantly better at inhibiting tumor volume
change compared to PTX nanosuspension. This is thought to be due to increased stability of
PTX-Trf, resulting in enhanced blood circulation in comparison with the control PTX
nanocrystals that aggregate in blood. Calculated tumor inhibition rates based on the
averaged weight of tumors dissected from the animals were 28.8% and 45.1% for PTX and
PTX-Trf nanosuspension treatment groups, respectively. The tumor inhibition rates between
these two groups were significantly different from each other (p<0.001). Combined with the
tumor progression results, the data indicate better treatment efficacy for PTX-Trf compared
to PTX alone. The results can be attributed to the presence of Trf in the formulation, which
may have played a role in stabilizing PTX nanocrystals as well as facilitated PTX
accumulation due to the presence of Trf receptors on surface of KB cells.
Interestingly, PTX solution in a 50:50 mixture of Cremophor EL and ethanol showed
significantly better tumor volume inhibition compared to both the other positive treatment
groups. By 12 days after initial injection, the average tumor volume in PTX solution treated
mice, had reached 257.1mm3 compared to 1,455 mm3 and 1,176 mm3 for PTX nanocrystal
and PTX-Trf formulation, respectively. The calculated tumor inhibition rate was 93.3% for
the PTX solution. This value was significantly (p<0.001) higher than the PTX-Trf and the
PTX nanosuspensions. However, while the antitumor efficacy of Taxol® was higher, its
toxicity was also significantly higher compared to the control and PTX nanocrystal
formulations. This is indicated in Figure 8, where the average body weight of mice over time
is shown. During the first 2 days, the average weight of mice treated by Taxol® decreased
by approximately 3.89% compared to an increase of 0.03% for the control and small
decreases of 0.58% and 0.29% for PTX nanocrystal and PTX-Trf formulations, respectively.
The high efficacy of Taxol in tumor growth inhibition has been observed in a previous study
utilizing KB cells as a model cell line [52]. This superior efficacy has been attributed to the
presence of Cremophor that forms micelles small enough to penetrate deeper into the tumor
mass compared to bigger nanocrystals [53, 54]. Studies have observed that Taxol
accumulates at a significantly higher extent compared to nanocrystals, which may have led
to the higher tumor inhibitory effect seen in the present study [55]. This suggests that the
amount of PTX-Trf accumulated at the tumor site may be between those of Taxol and PTX
nanocrystals. But the quantity is around 1% of the total administered dose [55], and at that
level, the anti-tumor effect may be mainly due to PTX that is absorbed into the tumor cells,
rather than the amount deposited near tumor. This makes sense, since Taxol provide better
PTX solubility than PTX-Trf, which in turn provides better solubility than PTX nanocrystals
which are prone to aggregate. Although the efficacy of Taxol was greater here, its toxicity
was also higher, which is a common concern that limits its usage. In comparison, the PTX-
Trf formulation demonstrated reasonable tumor inhibitory effect with minor toxicity issues
compared withthe control. The reduced toxicity by the nanocrystal formulation may be
significant enough for clinical applications, as demonstrated by the Doxil® formulation [56].
The ultimate goal of PTX-Trf approach is to develop a formulation that is as effective as or
better than Taxol, but with lower toxicity. Such a goal can be achieved through further
improvement and optimization of nanocrystal properties, e.g., nanocrystal size and Trf
coating, which can affect biodistribution of PTX.
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4. Conclusion
In the current study, a PTX nanocrystal formulation based on stabilization with Trf was
successfully developed. To ourknowledge, the approach of non-covalently modifying
anticancer drug nanocrystals with serum protein taken in this study has yet to be employed
elsewhere. Stable nanoparticles (less than 350 nm) containing PTX and Trfwere prepared in
a simple manner without complex chemical reactions. The non-covalently modified PTX
formulation was found to be stable over at least 3 months at 4 °C. In vivo antitumor
activities of PTX were significantly enhanced by the addition of Trf in comparison to just
the PTX nanocrystal alone. Overall, this study suggests the potential benefit of using a
serum protein in a non-covalent manner in conjunction with PTX nanocrystalsas a
promising drug delivery model for anticancer therapy, especially with reduced side effects.
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Figure 1.
Flow chart of the parameter optimization process to prepare PTX nanocrystals of desired
size.
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Figure 2.
Overview of the serum fractionation method used and resultant SDS-PAGE analysis of the
four different fractions
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Figure 3.
Effect of various serum protein fractions on PTX size change after incubation and
centrifugation.
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Figure 4.
X-ray diffractogram of pure PTX, Trf, physical mixtures and PTX-Trf formulation.
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Figure 5.
In vitro release profiles of PTX in phosphate buffer, pH 7.4.
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Figure 6.
In vitro cytotoxicity profiles of PTX nanocrystals and PTX-Trf formulation in SKOV-3 and
KB cells.
Lu et al. Page 22
J Control Release. Author manuscript; available in PMC 2015 February 28.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Figure 7.
In vivo antitumor efficacy of PTX formulations in mice.
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Figure 8.
Body weight change of mice after administration of various PTX formulations.
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Table 1
Summary of PTX nanocrystal size and PDI under various processing conditions
Average particle size (nm) PDI
Solvent Ethanol 287± 8 0.20
Methanol 280±15 0.15
DCM 338±13 0.09
EA 418±20 0.20
DMSO 353±13 0.21
PTX concentration 1 mg/ml 296±12 0.13
3 mg/ml 268±8 0.20
5 mg/ml 1,670±89 0.40
9 mg/ml 4,421±144 0.39
12 mg/ml 4,358±103 0.32
Antisolvent-solvent ratio 40:1 291±10 0.12
20:1 287±8 0.20
10:1 518±19 0.30
5:1 746±25 0.30
Stabilizer HPMC 490±19 0.25
PVP 514±23 0.19
PEG400 303±11 0.14
Pluronic F68 330±18 0.20
Pluronic F127 278±10 0.20
Tween 20 353±14 0.14
Tween 80 290±12 0.19
SDS 379±21 0.17
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Table 2
Effect of serum proteins HSA, Trf and IgG on PTX nanocrystal size
Concentration Average particle size (nm) % change from original
HSA 2 mg/ml 443± 24 70
10 mg/ml 400± 20 54
20 mg/ml 383± 23 34
40 mg/ml 352± 25 23
50 mg/ml 326± 20 13
Trf 3 mg/ml 400± 14 40
4 mg/ml 304± 13 6
IgG 3 mg/ml 1541 ± 102 437
10 mg/ml 1825 ± 128 536
10 mg/ml, pH 4.7 534± 39 86
10 mg/ml, 10% sucrose 360± 24 26
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Table 3
Particle size, PDI and ZP characterizations after storage at 4 °C
Duration Particle Size
(nm)
PDI Zeta Potential
(mV)
0 303 ± 11.1 0.124 − 13.6
1 month 296 ± 13.4 0.136 − 11.8
2 months 305 ± 9.9 0.118 − 13.4
3 months 301 ± 14.2 0.129 −14.7
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